Plus, news about EXO Biologics:
Centessa prices public offering: The startup aims to raise $93.5 million, or up to $107.6 million if all options are exercised. The funding would extend its runway into mid-2026. On Monday, Centessa announced the FDA cleared the IND for its narcolepsy program, called ORX750. A Phase 1 healthy volunteer study is set to start dosing “imminently,” with data expected in the second half of this year. — Max Gelman
Vivoryon axes Ph2 Alzheimer’s trial: The German biotech is dropping the Phase 2 VIVA-MIND test of varoglutamstat in early Alzheimer’s disease after the Phase 2b VIVIAD trial of the same asset failed in March. The move should extend Vivoryon’s cash runway into the second quarter of 2025, as it reconsiders its development strategy for varoglutamstat. — Ayisha Sharma
EXO Biologics completes €16M Series A: The funds are expected to support the company’s specialist CDMO subsidiary, ExoXpert(R), as well as ongoing and future clinical trials. EXO will also continue with its manufacturing expansion, including upgrading its ExoPulse production platform. — Ayisha Sharma